Latest Period
Q1 2026
Security Snapshot
Editas Medicine, Inc. - Common Stock (EDIT) Institutional Ownership
CUSIP: 28106W103
13F Institutional Holders and Ownership History from Q1 2016 to Q2 2026
Institutions Reporting
206
Shares (Excl. Options)
51,834,566
Price
$2.47
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- EDIT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 51,834,566
- Total 13F value
- $127,500,325
- Portfolio coverage rank
- 0%
- Share change
- +2,096,400
- Value change
- +$5,933,007
- Number of holders
- 206
- Shares outstanding
- 168,120,483
- SEC-reported price per share
- $3.16
- Insider filing price
- $3.16
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- EDIT - Editas Medicine, Inc. - Common Stock is tracked under CUSIP 28106W103.
- 206 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 206 to 56 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $127,500,325 to $3,739,879.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 206 institutions filings for Q1 2026.
Security key
28106W103
Latest holder period
Q1 2026
13F holders
206
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
EDIT full holder history
Editas Medicine, Inc. SEC filings
Editas Medicine, Inc. company facts
Editas Medicine, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 28106W103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
EDIT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | $51,025,650 | 16,045,802 | Commodore Capital LP | 26 May 2026 | |||
| TCG Crossover GP III, LLC | 9.9% | $50,240,817 | 15,798,999 | TCG Crossover GP III, LLC | 27 May 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 5.8% | $28,267,020 | 8,889,000 | RA Capital Management, L.P. | 27 May 2026 | |||
| BlackRock, Inc. | 5% | -37% | $27,072,105 | +$5,885,479 | 8,355,588 | +28% | BlackRock, Inc. | 30 Jun 2026 |
As of 31 Mar 2026, 206 institutional investors reported holding 51,834,566 shares of Editas Medicine, Inc. - Common Stock (EDIT). This represents 31% of the company’s total 168,120,483 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
27%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5.5% | 9,263,312 | -0.9% | 0% | $22,880,381 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 4,204,369 | 0% | 0% | $10,384,791 |
| RENAISSANCE TECHNOLOGIES LLC | 2.4% | 3,972,160 | +31% | 0.02% | $9,811,235 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.9% | 3,148,570 | 0% | 0% | $7,776,968 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 2,311,789 | +1.2% | 0% | $5,711,437 |
| STATE STREET CORP | 1.2% | 2,076,122 | +5.1% | 0% | $5,128,021 |
| Nuveen, LLC | 1.2% | 1,977,509 | +0.03% | 0% | $4,884,447 |
| JPMORGAN CHASE & CO | 1.2% | 1,947,384 | +149% | 0% | $4,342,666 |
| D. E. Shaw & Co., Inc. | 1.2% | 1,943,893 | +75% | 0% | $4,801,415 |
| Opaleye Management Inc. | 1.1% | 1,926,997 | 0.66% | $4,759,683 | |
| TWO SIGMA INVESTMENTS, LP | 0.92% | 1,549,063 | -5.1% | 0% | $3,826,186 |
| ACADIAN ASSET MANAGEMENT LLC | 0.87% | 1,457,715 | +82% | 0.01% | $3,596,000 |
| AQR CAPITAL MANAGEMENT LLC | 0.82% | 1,370,497 | +113% | 0% | $3,385,127 |
| RAYMOND JAMES FINANCIAL INC | 0.77% | 1,293,848 | +9.2% | 0% | $3,195,805 |
| KENNEDY CAPITAL MANAGEMENT LLC | 0.63% | 1,052,457 | +87% | 0.06% | $2,599,569 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.51% | 861,326 | +8.4% | 0% | $2,127,475 |
| NORTHERN TRUST CORP | 0.44% | 742,443 | +12% | 0% | $1,833,834 |
| MACKENZIE FINANCIAL CORP | 0.43% | 730,054 | 0% | $1,803,233 | |
| CITADEL ADVISORS LLC | 0.39% | 662,389 | -19% | 0% | $1,636,101 |
| VANGUARD FIDUCIARY TRUST CO | 0.37% | 614,036 | 0% | 0% | $1,516,669 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.35% | 582,309 | -30% | 0.01% | $1,438,303 |
| GOLDMAN SACHS GROUP INC | 0.33% | 558,577 | -37% | 0% | $1,379,685 |
| GSA CAPITAL PARTNERS LLP | 0.26% | 434,413 | -24% | 0.07% | $1,073,000 |
| MORGAN STANLEY | 0.24% | 411,192 | -39% | 0% | $1,015,644 |
| UBS Group AG | 0.23% | 393,754 | -51% | 0% | $972,572 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
42
Latest
Q1 2026
Rows shown
1-25 of 42
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 1,148,506 | $3,739,879 | +$897,296 | $3.24 | 56 |
| 2026 Q1 | 51,834,566 | $127,500,325 | +$5,933,007 | $2.47 | 206 |
| 2025 Q4 | 49,948,580 | $102,489,972 | +$13,818,867 | $2.05 | 192 |
| 2025 Q3 | 43,042,863 | $149,310,576 | +$7,918,428 | $3.47 | 191 |
| 2025 Q2 | 41,335,195 | $90,959,890 | -$2,651,384 | $2.20 | 190 |
| 2025 Q1 | 44,017,732 | $51,056,496 | -$8,643,822 | $1.16 | 189 |
| 2024 Q4 | 51,050,083 | $64,829,211 | -$26,980,305 | $1.27 | 199 |
| 2024 Q3 | 55,026,910 | $187,727,875 | -$7,609,494 | $3.41 | 223 |
| 2024 Q2 | 56,388,612 | $263,332,828 | -$55,730,958 | $4.67 | 229 |
| 2024 Q1 | 67,934,083 | $503,995,838 | +$62,859,602 | $7.42 | 221 |
| 2023 Q4 | 58,810,431 | $595,736,469 | -$24,830,057 | $10.13 | 222 |
| 2023 Q3 | 61,671,930 | $481,001,719 | -$15,318,112 | $7.80 | 220 |
| 2023 Q2 | 62,806,728 | $516,820,804 | +$83,105,555 | $8.23 | 234 |
| 2023 Q1 | 52,966,709 | $383,993,662 | -$13,671,500 | $7.25 | 231 |
| 2022 Q4 | 54,069,648 | $479,580,650 | +$43,275,611 | $8.87 | 245 |
| 2022 Q3 | 48,268,099 | $590,813,665 | +$8,782,042 | $12.24 | 243 |
| 2022 Q2 | 47,470,750 | $561,353,937 | +$5,825,446 | $11.83 | 235 |
| 2022 Q1 | 45,377,308 | $862,213,005 | -$137,494,973 | $19.02 | 239 |
| 2021 Q4 | 50,935,353 | $1,354,989,098 | -$58,058,784 | $26.55 | 288 |
| 2021 Q3 | 51,686,909 | $2,124,275,170 | -$9,901,736 | $41.08 | 307 |
| 2021 Q2 | 52,115,846 | $2,960,972,143 | -$42,349,447 | $56.64 | 309 |
| 2021 Q1 | 53,112,966 | $2,230,651,006 | -$37,048,235 | $42.00 | 296 |
| 2020 Q4 | 52,925,101 | $3,710,809,621 | -$146,422,850 | $70.11 | 303 |
| 2020 Q3 | 55,153,663 | $1,547,459,830 | +$15,957,942 | $28.06 | 233 |
| 2020 Q2 | 54,180,331 | $1,601,145,803 | +$263,790,568 | $29.58 | 225 |